<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00392743</url>
  </required_header>
  <id_info>
    <org_study_id>TMT108154</org_study_id>
    <nct_id>NCT00392743</nct_id>
  </id_info>
  <brief_title>A Study to Compare Two Different Brain Imaging Techniques in Healthy Volunteers and in Schizophrenic Patients</brief_title>
  <official_title>An Open-label, Cross-over Study, to Compare the PET and SPECT Measurement of Antipsychotic-induced D2 Receptor Occupancy, in a Group of Healthy Volunteers and in Another Group of Patients With Schizophrenia and Other Psychotic Disorders</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>GlaxoSmithKline</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>GlaxoSmithKline</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      A direct comparison of Positron Emission Tomography (PET) (11C-Raclopride) and Single Photon
      Emission Computed Tomography (SPECT) (123I-IBZM) D2 RO measurements would allow GSK to gain
      understanding on the SPECT results obtained with SB773812, and to accurately interpret future
      D2 RO results from either PET or SPECT studies with new compounds.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>December 2006</start_date>
  <completion_date type="Actual">May 2007</completion_date>
  <primary_completion_date type="Actual">May 2007</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <primary_outcome>
    <measure>PET and SPECT striatal binding potential</measure>
    <time_frame>at day 1</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>plasma concentrations at the time of scanning,</measure>
    <time_frame>at day 1</time_frame>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Actual">60</enrollment>
  <condition>Schizophrenia</condition>
  <arm_group>
    <arm_group_label>pet/spect scan</arm_group_label>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>pet/spect scan</intervention_name>
    <arm_group_label>pet/spect scan</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        This is a methodology study.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion criteria:

          -  Not pregnant or becoming pregnant during the study.

          -  No abnormality in clinical examination, clinical laboratory test or ECG.

          -  Not taking drugs

          -  Patients with schizophrenia, schizophreniform disorder or schizoaffective disorders.

          -  Patients with at least 1 month antipsychotic monotherapy with either risperidone,
             olanzapine or clozapine.

          -  Healthy volunteers with no neurological or psychiatric illness.

        Exclusion criteria:

          -  Have received other antipsychotic during the last month or neuroleptics during the
             last year.

          -  If you have taken part in investigations you should not receive a radiation dose of
             more than 10 mSv over any 3 year period.

          -  History of bleeding disorder or are taking medication that affects blood clotting

          -  History of substance dependence (except nicotine)

          -  Claustrophobia

          -  Gross head deformity.

          -  Unable to lie still in the PET or SPECT camera for 1 hour and a half.

          -  The presence of a cardiac pacemaker or other electronic device or ferromagnetic metal
             foreign bodies.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>GSK Clinical Trials</last_name>
    <role>Study Director</role>
    <affiliation>GlaxoSmithKline</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Barcelona</city>
        <zip>08003</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Barcelona</city>
        <zip>08025</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Barcelona</city>
        <zip>08035</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Barcelona</city>
        <zip>08036</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Barcelona</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Espluges de Llobregat</city>
        <zip>08950</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Sant Boi de Llobregat</city>
        <zip>08830</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <verification_date>October 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 24, 2006</study_first_submitted>
  <study_first_submitted_qc>October 24, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 26, 2006</study_first_posted>
  <last_update_submitted>November 1, 2012</last_update_submitted>
  <last_update_submitted_qc>November 1, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 5, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Bolus</keyword>
  <keyword>11C-Raclopride</keyword>
  <keyword>Schizophrenia</keyword>
  <keyword>123I-IBZM</keyword>
  <keyword>SPECT</keyword>
  <keyword>Receptor Occupancy</keyword>
  <keyword>PET</keyword>
  <keyword>MRI</keyword>
  <keyword>Antipsychotics</keyword>
  <keyword>Bolus/Infusion</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Schizophrenia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Antipsychotic Agents</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

